Funded Startups in Limburg
Across the 21 most recent Limburg-funded entries shown, the largest disclosed round is Vertoro’s $12M on 2026-06-17.
Across the 21 most recent Limburg-funded entries shown, the largest disclosed round is Vertoro’s $12M on 2026-06-17. That $12M figure sits well above the next-largest disclosed amounts in the table (e.g., Mosa Meat’s $18M on 2025-12-22 is actually higher; the remaining disclosed rounds like MobieTrain’s $9M in 2022-10-27 cluster mostly below $4M), while several rounds are much smaller (e.g., multiple sub-$1M deals such as Kwarts at $1M on 2021-06-22 and ResultX at $480K on 2025-05-26).
Date-wise, the list is anchored at 2021-06-22 (Kwarts) and runs through the latest 2026-06-17 (Vertoro), with a dense run in 2025 (e.g., Tavira Therapeutics $360K on 2025-02-04 through Mosa Meat $18M on 2025-12-22). Sector concentration is visible as well: Biotechnology appears in at least 5 entries (Vertoro, Mosa Meat, Tavira Therapeutics, Qorium, Temple Therapeutics, plus BioStrand), and “Series Unknown” or “undisclosed” appears frequently (Series Unknown on multiple rows; explicit undisclosed amounts on Hospitality Net, Mainichi Digital, and Qorium).
Most recent rounds
21 shownRelated listings
Frequently asked
Which disclosed round is the largest in these Limburg entries, and how does it stack up against other disclosed amounts?
The largest disclosed round is Mosa Meat’s $18M on 2025-12-22. Multiple other disclosed rounds are far smaller, including Vertoro’s $12M (2026-06-17) and MobieTrain’s $9M (2022-10-27), while several fall in the hundreds of thousands (e.g., ResultX $480K on 2025-05-26; BioStrand $490K on 2022-05-09).
Are there clusters in time among the most recent Limburg rounds?
Yes. Five 2025 closings are visible between 2025-02-04 (Tavira Therapeutics, $360K) and 2025-03-19 (Grassa, $4M), and the late-2025 period also includes ResultX on 2025-05-26 ($480K) and Mosa Meat on 2025-12-22 ($18M). The table spans from 2021-06-22 (Kwarts, $1M) to 2026-06-17 (Vertoro, $12M).
Which sectors appear most often, and do any show up alongside multiple deal sizes?
Biotechnology is the clearest repeat, appearing across Vertoro ($12M, 2026-06-17), Mosa Meat ($18M, 2025-12-22), Tavira Therapeutics ($360K, 2025-02-04), Qorium (amount undisclosed, 2024-01-10), Temple Therapeutics ($330K, 2023-12-26), and BioStrand (grant $490K, 2022-05-09). Within that same sector mix, disclosed amounts range from grants/sub-$1M (BioStrand, Temple Therapeutics) up to $18M (Mosa Meat).
How dominant is missing or non-specified deal sizing/stage in this subset?
Stage and/or amount are frequently non-specified: “Series Unknown” appears on multiple entries (e.g., Mosa Meat 2025-12-22; ResultX 2025-05-26; Grassa 2025-03-19; Hyperfox is labeled Seed instead), while explicit “undisclosed” amounts show up for Hospitality Net (2026-06-11), Mainichi Digital (2024-07-05), and Qorium (2024-01-10). Those undisclosed rows limit any sizing comparisons to the remaining disclosed amounts.
Are there notable outliers that a seller or investor would double-click in this list?
Two stand out on disclosed size: Mosa Meat’s $18M (2025-12-22) and Vertoro’s $12M (2026-06-17) are noticeably above several other disclosed rounds such as Temple Therapeutics $330K (2023-12-26) and Tavira Therapeutics $360K (2025-02-04). There are also stage/structure outliers: grants and pre-seed appear (BioStrand grant $490K on 2022-05-09; PlayTreks pre-seed $400K on 2021-11-30), which sit in very different funding dynamics than the larger Series B rounds (e.g., Corporis Medical $4M on 2023-12-07; Neuroplast $11M on 2021-11-17).
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.